Sumitoma Pharma US
Tiffany Campbell 庭葉新 歓辺留 serves as the Director of Pharmacovigilance at Sumitomo Pharma America, Inc., a position held since July 2023. Previously, Tiffany held various roles at Sunovion Pharmaceuticals from March 2018 to June 2023, including Associate Director and Principal Scientist in Pharmacovigilance, and gained extensive experience at Sanofi Genzyme from May 2005 to March 2018, working as a Scientist and Senior Associate in pharmacovigilance and safety signal management. Tiffany's expertise encompasses signal detection, safety evaluations, risk management plan development, and regulatory compliance, along with supervisory experience in managing teams and projects related to medical information and safety governance. Education includes a Bachelor of Science in Politics and History from Willamette University and a research grant from UCL focusing on Political Theory.
This person is not in any teams
This person is not in any offices
Sumitoma Pharma US
2 followers
Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in oncology, urology, women’s health, rare disease, cell and gene therapies and psychiatry and neurology.